Evidence map›Paper›PMID 41845473›Full record

ArticleBMC pediatrics2026

Evaluating oxidative stress marker F

Kameelah Gateau, Ramon Durazo-Arvizu, Pat Levitt

Abstract read
In one paragraph

Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kameelah GateauDivision of Neonatology, Department of Pediatrics, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. kgateau@chla.usc.edu.
Ramon Durazo-ArvizuDivision of Neurology, Department of Pediatrics, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Pat LevittDivision of Neurology, Department of Pediatrics, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

Funding

IH National Institutes of Health & NCATS National Center for Advancing Translational Science UL1-TR001855
6 · The paper itself

Abstract

backgroundExperiencing early life adversity (ELA) and chronic stress activation early in childhood increases the risk for altered developmental trajectories that lead to lifelong impacts on physical and mental health. This results in a toxic stress response – the dysregulation of neuroendocrine, immune and metabolic functions that causes allostatic load and a higher risk for poor health. Current screening practices for identifying toxic stress is the typical use Adverse Childhood Experience (ACEs) questionnaires, for which higher scores have strong predictability of outcomes at a population level. However, when used as the sole ELA identification tool, the questionnaire has challenges predicting later health outcomes at the individual level. We have proposed that the adaptative processes to ELA converge on mitochondrial health and is measurable in several ways, including the gold standard marker of oxidative stress due to reactive oxygen species, F2α-Isoprostanes (F2α -IsoPs). The major initiation of F2α-IsoPs formation is reactive oxygen species (ROS) accumulation, a major source of which is mitochondria. This study aimed to evaluate the relation between maternal ACEs, child F2α-IsoPs measures, and child neurodevelopment, establishing how the relations change over early developmental periods.

methodsIn our ongoing “Family First” longitudinal study, F2α-IsoPs were measured from child urine samples collected at 6-,12-, and 24 months. Maternal adversity was assessed using the ACEs questionnaire at 6- and scores were confirmed at 12-months. The Bayley Scales of Infant Development (Bayley-4) was administered to assess child neurodevelopment at all study time points.

resultsElevated infant F2α-IsoPs at 6 months correlated significantly with lower language ( r=-0.15,p = 0.02) and motor scores (r=-0.16,p = 0.02) as assessed by the Bayley-4. Assessment of the relation between maternal ACEs on changes in infant F2α-IsoPs levels over the first year of life demonstrated there were significantly different F2α-IsoPs (15-F2t-IsoP, p = 0.003) and (5-F2t-IsoP, p = 0.001) trajectories for infants whose mothers endorsed either 0, 1–2, or 3 + on ACEs. Changes in child Bayley-4 scores in the second year of life varied by maternal ACEs with children whose mothers had no endorsements of adversity had decreasing language and motor scores and children whose mothers had any endorsements on ACEs had increasing language(p = 0.02) and motor scores (p = 0.02).

conclusionsThe data indicate that there may be specific physiologic contributions of oxidative stress to a toxic stress response in young children. A broader approach to pediatric screening for toxic stress predictability may be the incorporation of F2α-IsoPs as one of the physiologic measures in the first two years postnatally.

Indexed as

Adverse Childhood ExperiencesChild DevelopmentF2-IsoprostanesOxidative StressStress, PsychologicalBiomarkersChild, PreschoolFemaleHumansInfantMaleNeurodevelopmentBiomarkersF2-IsoprostanesBiomarkersEarly childhood developmentEarly life adversityIsoprostanes

Identifiers

PMID41845473
PMCPMC13107758

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.